【摘要】 目的分析晚期肺腺癌表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变率及其与临床特征的相关性。方法收集2010-09-07-2011-07-21首都医科大学附属北京胸科医院收治的晚期初治肺腺癌患者102例,有可供检测的肿瘤组织标本。利用扩增受阻突变系统(amplification refractory mutation system,ARMS)进行EGFR基因突变检测,统计分析EGFR基因突变状态和临床特征的相关性。结果 102例晚期肺腺癌组织中,共检测到EGFR基因突变55例(53.9%),其中18外显子突变1例(1.0%),19外显子突变25例(24.5%),20外显子突变2例(2.0%),21外显子突变26例(25.5%),同时存在19和20外显子突变1例(1.0%)。Ⅳ期患者EGFR基因突变率为57.6%(53/92),高于ⅢB期患者20.0%(1/10),差异有统计学意义,P=0.041;女性患者EGFR基因突变率56.9%(33/58)高于男性患者的50.0%(22/44),不吸烟患者EGFR基因突变率58.1%(36/62)高于吸烟患者的36.0%(9/25),<65岁患者EGFR基因突变率56.8%(42/74)高于≥65岁患者的46.4%(13/28),但差异均无统计学意义,P>0.05。不同取材部位及取材方法之间EGFR基因突变率差异无统计学意义,P>0.05。结论晚期肺腺癌EGFR基因突变率以Ⅳ期、女性和不吸烟患者较高,但性别及吸烟状态之间的差异无统计学意义。不同的肿瘤活检部位及活检方法之间EGFR基因突变率并无差异。更多还原

【Abstract】 OBJECTIVE To assess EGFR mutation rates in patients with advanced lung adenocarcinoma and the influences of demographic and clinical factors on EGFR mutation rates were investigated.METHODS Totally 102 patients with stageⅢB/Ⅳlung adenocarcinoma treated in our hospital were included.The EGFR mutation status of the tumor sample were determined using Scorpion ARMS.EGFR mutation frequency was calculated and compared between demographic/clinical factor subgroups(Fisher’s exact test).RESULTS Totally 102 cases of advanced lung adenocarcinoma,EGFR mutations were detected in 55cases(53.9%).There were 1case of the mutation in exton 18(1.0%),25 cases of the mutation in exton 19(24.5%),2cases of the mutation in exton 20(2.0%),26 cases of the mutation in exton 21(25.5%),including 1case mutation both in exton 19 and 20(1.0%).In stage Ⅳ patients the mutation rates of EGFR were(57.6%,53/92),which was higher than that in patients with stageⅢB(20%,1/10),the difference was statistically significant(P=0.041).Mutation was more frequently observed in female(56.9%,33/58)than that in male(50.0%,22/44)and in non-smokers(58.1%,36/62)than that smokers(36.0%,9/25),in <65-year-old(56.8%,42/74)than that in≥65-year-old(46.4%,13/28),but the difference did not reach statistical significance(P>0.05).Different biopsy sites and types between EGFR mutation rate were not statistically significant(P>0.05).CONCLUSIONS The overall EGFR mutation rate in in advanced lung adenocarcinoma was 53.9%,of which stage Ⅳ,female,non-smoking patients was higher.Between different biopsy site and type,EGFR mutation rate did not differ.更多还原